Drugs Affecting Blood and Blood Formation Practice Questions

Q: All are antiplatelet drugs except:

Aprotinin. ***Aprotinin*** - **Aprotinin** is a **serine protease inhibitor** used to reduce bleeding during complex surgeries, particularly cardiac surgery. - It works by inhibiting kallikrein and plasmin, thereby **preserving platelets** and **reducing fibrinolysis**, rather than inhibiting platelet aggregation. *Clopidogrel* - **Clopidogrel** is a **P2Y12 receptor inhibitor** that prevents platelet activation and aggregation. - It is commonly used in patients with **acute coronary syndrome** and for the prevention of thrombotic events. *Abciximab* - **Abciximab** is a **glycoprotein IIb/IIIa receptor antagonist** that blocks the final common pathway of platelet aggregation. - It is primarily used during **percutaneous coronary intervention (PCI)** to prevent ischemic complications. *Ticlopidine* - **Ticlopidine** is another **P2Y12 receptor inhibitor** that inhibits platelet aggregation similar to clopidogrel. - It is associated with a higher risk of **hematologic side effects** like neutropenia and thrombotic thrombocytopenic purpura (TTP) compared to clopidogrel.

Q: Which of the following is a non-peptide GP IIb/IIIa antagonist?

Tirofiban. **Tirofiban** is the correct answer as it is a **non-peptide GP IIb/IIIa antagonist**. ***Tirofiban*** - Tirofiban is a **non-peptide GP IIb/IIIa antagonist** (tyrosine derivative) that blocks the binding of **fibrinogen** to the receptor, thereby inhibiting platelet aggregation. - Its **small molecular weight** and **reversible binding** allow for rapid onset and offset of action. - Used in acute coronary syndromes and during percutaneous coronary interventions. *Abciximab* - Abciximab is the **Fab fragment** of a **monoclonal antibody** directed against the GPIIb/IIIa receptor, making it a **peptide-based** (antibody-based) antagonist. - It has high affinity for the receptor and a relatively **long duration of action** due to its antibody nature. *Eptifibatide* - Eptifibatide is a **cyclic heptapeptide** that mimics the RGD (arginine-glycine-aspartate) sequence found in fibrinogen, classifying it as a **peptide-based** antagonist. - It selectively binds to the **GPIIb/IIIa receptor**, preventing platelet aggregation. *Prasugrel* - Prasugrel is a **thienopyridine P2Y12 inhibitor**, which acts by irreversibly blocking the **ADP receptor** on platelets, preventing their activation and aggregation. - It is distinct from GP IIb/IIIa inhibitors as it targets a **different pathway of platelet activation** (not a GP IIb/IIIa antagonist at all).

Q: What is the mechanism of action of Clopidogrel?

Inhibition of ADP-mediated platelet activation. ***Inhibition of ADP-mediated platelet activation*** - Clopidogrel is an **antiplatelet agent** that works by a direct antagonistic action at the **P2Y12 receptor** on the surface of platelets. - This binding prevents adenosine diphosphate (ADP) from binding to its receptor, thereby inhibiting the activation of the **GP IIb/IIIa receptor complex** and subsequent platelet aggregation. *Inhibition of Thromboxane A2* - This mechanism of action is characteristic of **aspirin**, which inhibits the enzyme **cyclooxygenase-1 (COX-1)**. - COX-1 inhibition leads to reduced production of **Thromboxane A2**, a potent platelet aggregator and vasoconstrictor. *Inhibition of GP IIb/IIIa receptors* - While Clopidogrel ultimately affects the activation of **GP IIb/IIIa receptors**, it does not directly inhibit them. - Drugs like **abciximab**, **eptifibatide**, and **tirofiban** are direct inhibitors of the GP IIb/IIIa receptors, preventing fibrinogen binding and platelet aggregation. *No effect on platelet activation* - This statement is incorrect as Clopidogrel is a well-established **antiplatelet drug**. - Its therapeutic effect is specifically to **reduce platelet activation** and aggregation, thus preventing thrombotic events.

Q: Which of the following is most likely to be used in a young child with chronic renal insufficiency?

Erythropoietin (EPO). ***Erythropoietin (EPO)*** - **Chronic renal insufficiency** leads to decreased production of **erythropoietin** by the kidneys, resulting in **anemia**. - Administering exogenous **EPO** stimulates red blood cell production, correcting the anemia common in these patients. *Desferrioxamine* - This is a **chelating agent** used to treat **iron overload**, which can occur in patients receiving multiple blood transfusions or those with certain genetic disorders. - While some chronic renal patients may receive transfusions, **iron overload** is not the primary or most common issue addressed by this medication in the context of general renal insufficiency. *Filgrastim (G-CSF)* - **Granulocyte colony-stimulating factor (G-CSF)** is used to stimulate the production of **neutrophils**, typically in patients with **neutropenia** (low white blood cell count) due to chemotherapy or certain bone marrow disorders. - It does not directly address the primary hematological complications of chronic renal insufficiency, which is mainly **anemia**. *Cyanocobalamin (Vitamin B12)* - **Vitamin B12** is essential for red blood cell formation and neurological function; its deficiency can cause **megaloblastic anemia**. - While renal insufficiency can affect nutrient absorption, **B12 deficiency anemia** is not the most common or direct hematological complication of chronic kidney disease, which is primarily due to EPO deficiency.

Q: Folic acid deficiency is precipitated by:

Methotrexate. ***Methotrexate*** - **Methotrexate** is an **antimetabolite** that acts as a **folic acid analog**, competitively inhibiting **dihydrofolate reductase (DHFR)**, the enzyme responsible for converting dihydrofolate to tetrahydrofolate. - This inhibition blocks **DNA synthesis** and cell proliferation, leading to the therapeutic effects of methotrexate but also causing **severe folic acid deficiency** by preventing the formation of its active form. - **Most direct and potent** cause of drug-induced folate deficiency, requiring **leucovorin rescue** in high-dose therapy. *Phenytoin* - **Phenytoin** is an **antiepileptic drug** that **interferes with folate absorption** by inhibiting **intestinal conjugase enzyme** and affecting folate transport mechanisms. - Chronic use can lead to **clinically significant folate deficiency** and **megaloblastic anemia**, making it an important recognized cause. - However, compared to methotrexate, the mechanism is **indirect** (absorption interference) rather than direct enzyme inhibition, and the onset is more gradual. *Trimethoprim* - **Trimethoprim** also inhibits **dihydrofolate reductase**, but its affinity for **bacterial DHFR** is significantly higher (thousands of times) than for human DHFR. - While prolonged high-dose use can rarely cause **folate deficiency** in humans, it is much less common and clinically significant than with methotrexate or phenytoin. *Cyclosporin* - **Cyclosporin** is an **immunosuppressant** that primarily acts by inhibiting **calcineurin**, thereby preventing the activation of **T-lymphocytes**. - Its mechanism of action does not directly involve **folic acid metabolism**, and it is **not known** to cause folic acid deficiency.

Q: All of the following are antiplatelet agents except which of the following?

Tranexamic acid. ***Tranexamic acid*** - **Tranexamic acid** is an **antifibrinolytic agent** that inhibits plasminogen activation, thereby preventing clot breakdown. - It works to **promote clot stability** and is used to reduce bleeding, rather than inhibit platelet aggregation. *Aspirin* - **Aspirin** is an **antiplatelet agent** that irreversibly inhibits **cyclooxygenase-1 (COX-1)**, reducing thromboxane A2 production. - This effectively prevents platelet aggregation and is used for primary and secondary prevention of cardiovascular events. *Clopidogrel* - **Clopidogrel** is a **P2Y12 inhibitor**, an antiplatelet agent that selectively and irreversibly blocks the ADP receptor on platelets. - This inhibition prevents activation of the GP IIb/IIIa complex, thereby reducing **platelet aggregation**. *Ticagrelor* - **Ticagrelor** is a **P2Y12 inhibitor**, an antiplatelet agent that reversibly binds to the ADP receptor on platelets. - It provides a rapid and potent inhibition of **platelet aggregation**, similar to clopidogrel but with a faster onset and offset of action.

Q: What was the first oral direct thrombin inhibitor to be developed and approved for clinical use?

Ximelagatran. ***Ximelagatran*** - **Ximelagatran** was the **first oral direct thrombin inhibitor** to be developed and approved for clinical use. - Despite its initial approval, it was later withdrawn due to concerns about **drug-induced liver injury**. *Indraparinux* - **Indraparinux** is a **synthetic heparin analog** and an **indirect Factor Xa inhibitor**, not a direct thrombin inhibitor. - It was developed as a long-acting anticoagulant but did not achieve widespread clinical adoption. *Dabigatran* - **Dabigatran** is currently a widely used **oral direct thrombin inhibitor**, but it was approved **after ximelagatran**. - It is often cited as the first of the modern non-vitamin K antagonist oral anticoagulants (**NOACs**) to be widely marketed, but not the very first to be developed and approved for clinical use. *Fondaparinux* - **Fondaparinux** is a synthetic **selective Factor Xa inhibitor**, structurally similar to the antithrombin-binding region of heparin. - It works indirectly by enhancing antithrombin's activity against Factor Xa, and is not a direct thrombin inhibitor.

Q: What is the mechanism of action of ticagrelor?

P2Y12 receptor antagonist. ***P2Y12 receptor antagonist*** - **Ticagrelor** is an **oral antiplatelet drug** that reversibly binds to the **P2Y12 ADP receptor** on platelet surfaces. - By blocking this receptor, it prevents **ADP-mediated platelet activation** and subsequent aggregation, reducing the risk of thrombotic events. *Cox inhibition* - **COX inhibitors** like **aspirin** prevent the synthesis of **thromboxane A2**, a powerful platelet aggregator. - This mechanism is characteristic of **NSAIDs** and **aspirin**, not ticagrelor. *GPIIB/IIIA inhibition* - **GPIIb/IIIa inhibitors** (e.g., abciximab, eptifibatide, tirofiban) directly block the final common pathway for platelet aggregation by preventing **fibrinogen binding** to the GPIIb/IIIa receptor. - While also an antiplatelet mechanism, this is distinct from ticagrelor's action on the P2Y12 receptor. *Inhibition of thromboxane synthase* - Inhibition of **thromboxane synthase** would reduce the production of **thromboxane A2**, similar to the effect of COX inhibition. - This is not the primary mechanism of action for ticagrelor; drugs like **dazoxiben** or **picotamide** act through this pathway.

Q: A PTT is required for monitoring of which of the following anticoagulants?

Heparin. ***Heparin*** - The **activated partial thromboplastin time (aPTT or PTT)** is the standard laboratory test used to monitor the anticoagulant effect of **unfractionated heparin**. - Heparin primarily acts by enhancing the activity of **antithrombin III**, which inactivates factors like thrombin (Factor IIa) and Factor Xa, affecting the intrinsic and common pathways of coagulation, which the PTT measures. *Streptokinase* - Streptokinase is a **fibrinolytic agent** not an anticoagulant, meaning it dissolves clots rather than preventing their formation. - Its therapeutic effect is not monitored by PTT, but rather by assessing the lytic state, often through **fibrinogen levels** or euglobulin lysis time. *Warfarin* - **Warfarin** is monitored by the **prothrombin time (PT)** and subsequent international normalized ratio (INR). - Warfarin inhibits **vitamin K-dependent clotting factors** (II, VII, IX, X), which are primarily assessed by the PT. *Tranexamic acid* - Tranexamic acid is an **antifibrinolytic agent** that inhibits plasminogen activation, thus preventing the breakdown of fibrin clots. - It works to promote clot stability and is not an anticoagulant; therefore, it is not monitored by PTT.

Q: Which of the following statements about warfarin is false?

Warfarin does not cross the placenta. ***Warfarin does not cross the placenta*** - Warfarin **rapidly crosses the placenta**, leading to fetal exposure and potential teratogenic effects, such as **fetal warfarin syndrome**. - This characteristic makes warfarin generally **contraindicated during pregnancy**, especially in the first trimester. *Half-life is 25 to 60 hours* - The half-life of warfarin is indeed relatively long, ranging from approximately **25 to 60 hours**, which contributes to its once-daily dosing. - This prolonged half-life means that changes in dosing take several days to reach a **new steady-state** and affect the International Normalized Ratio (INR). *Inhibits vitamin K dependent clotting factor synthesis* - Warfarin functions as a **vitamin K antagonist**, inhibiting the hepatic synthesis of vitamin K-dependent clotting factors **II, VII, IX, and X**. - It achieves this by blocking **vitamin K epoxide reductase**, an enzyme essential for reactivating vitamin K. *Contraindicated in patients with severe hepatic failure* - Warfarin is primarily metabolized in the **liver** by cytochrome P450 enzymes, and its clotting factors are synthesized in the liver. - Therefore, **severe hepatic failure** can impair both warfarin metabolism and the production of clotting factors, leading to an increased risk of bleeding and making it a contraindication.

Question 1

All are antiplatelet drugs except:

Accepted Answer

Aprotinin

Answer

Clopidogrel

Answer

Abciximab

Answer

Ticlopidine

Question 2

Which of the following is a non-peptide GP IIb/IIIa antagonist?

Accepted Answer

Tirofiban

Answer

Abciximab

Answer

Eptifibatide

Answer

Prasugrel

Question 3

What is the mechanism of action of Clopidogrel?

Accepted Answer

Inhibition of ADP-mediated platelet activation

Answer

Inhibition of Thromboxane A2

Answer

Inhibition of GP IIb/IIIa receptors

Answer

No effect on platelet activation

Question 4

Which of the following is most likely to be used in a young child with chronic renal insufficiency?

Accepted Answer

Erythropoietin (EPO)

Answer

Desferrioxamine

Answer

Filgrastim (G-CSF)

Answer

Cyanocobalamin (Vitamin B12)

Question 5

Folic acid deficiency is precipitated by:

Accepted Answer

Methotrexate

Answer

Phenytoin

Answer

Trimethoprim

Answer

Cyclosporin

Question 6

All of the following are antiplatelet agents except which of the following?

Accepted Answer

Tranexamic acid

Answer

Clopidogrel

Answer

Ticagrelor

Answer

Aspirin

Question 7

What was the first oral direct thrombin inhibitor to be developed and approved for clinical use?

Accepted Answer

Ximelagatran

Answer

Indraparinux

Answer

Fondaparinux

Answer

Dabigatran

Question 8

What is the mechanism of action of ticagrelor?

Accepted Answer

P2Y12 receptor antagonist

Answer

Cox inhibition

Answer

Inhibition of thromboxane synthase

Answer

GPIIb/IIIa inhibition

Question 9

A PTT is required for monitoring of which of the following anticoagulants?

Accepted Answer

Heparin

Answer

Streptokinase

Answer

Warfarin

Answer

Tranexamic acid

Question 10

Which of the following statements about warfarin is false?

Accepted Answer

Warfarin does not cross the placenta

Answer

Half-life is 25 to 60 hours

Answer

Inhibits vitamin K dependent clotting factor synthesis

Answer

Contraindicated in patients with severe hepatic failure

Drugs Affecting Blood and Blood Formation — MCQs

Drugs Affecting Blood and Blood Formation — MCQs

On this page

Practice by Chapter

Want unlimited practice?